Skip to main content
. 2018 Oct 15;10(10):384. doi: 10.3390/cancers10100384

Table 3.

Risk of grade ≥3 diarrhea with afatinib treatment (40 mg or 50 mg starting dose) by count of risk factors 1.

Risk Factors 1 Events/Patients (%)
40 mg Afatinib 50 mg Afatinib
0 5/90 (6%) 9/119 (8%)
1 17/238 (7%) 51/312 (16%)
2 23/152 (15%) 64/198 (32%)
3 6/18 (33%) 9/21 (43%)

1 Female sex, age ≥60 years, and body weight <45 kg.